These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Bryson HM, Palmer KJ, Langtry HD, Fitton A. Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987 [Abstract] [Full Text] [Related]
7. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M. Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120 [Abstract] [Full Text] [Related]
8. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Faber TS, Camm AJ. Eur J Clin Pharmacol; 1996 May; 51(3-4):199-208. PubMed ID: 9010685 [Abstract] [Full Text] [Related]
9. Spectral analysis of short term R-Tapex interval variability during sinus rhythm and fixed atrial rate. Lombardi F, Sandrone G, Porta A, Torzillo D, Terranova G, Baselli G, Cerutti S, Malliani A. Eur Heart J; 1996 May; 17(5):769-78. PubMed ID: 8737109 [Abstract] [Full Text] [Related]
13. Clinical experience with propafenone for cardiac arrhythmias in the young. Heusch A, Kramer HH, Krogmann ON, Rammos S, Bourgeous M. Eur Heart J; 1994 Aug; 15(8):1050-6. PubMed ID: 7527342 [Abstract] [Full Text] [Related]
14. [Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases]. Coumel P, Leclercq JF, Assayag P, Maisonblanche P, Cauchemez B. Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1370-82. PubMed ID: 6439161 [Abstract] [Full Text] [Related]
15. Low-frequency component of the heart rate variability spectrum: a poor marker of sympathetic activity. Houle MS, Billman GE. Am J Physiol; 1999 Jan; 276(1):H215-23. PubMed ID: 9887035 [Abstract] [Full Text] [Related]
17. [Characteristics of action of various drugs blocking atrioventricular conduction (beta-blockers, verapamil, diltiazem) in constant fibrillation tachyarrhythmia. Is monotherapy optimal?]. Blagova OV, Nedostup AV. Ter Arkh; 2006 Jan; 78(8):30-8. PubMed ID: 17078214 [Abstract] [Full Text] [Related]
18. [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. Telichowski A, Banasiak W, Ponikowski P, Wiech K, Zebrowski J, Pieróg M, Kałka D, Lacheta W, Fuglewicz A, Molenda W. Pol Arch Med Wewn; 1995 Aug; 94(2):132-43. PubMed ID: 8596748 [Abstract] [Full Text] [Related]
19. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. Capucci A, Boriani G. Drug Saf; 1995 Jan; 12(1):55-72. PubMed ID: 7741984 [Abstract] [Full Text] [Related]